FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$1.19
+0.06 (+5.31%)
As of Mar 31, 3:11 PM ET ·
Analyst Consensus
Buy
18
Analysts
High
Coverage
Buy 11 61%
Hold 7 39%
Sell 0 0%
Price Target
Analyst Price Target +383.2% upside
Low Target $4.43
Average Target $5.75
High Target $6.69
Current Price $1.19
Current
$1.19
Target
$5.75
$4.43 $5.75 avg $6.69
Scenario Analysis
Bear Case
$4.43
272.3%
Low target
Base Case
$5.75
+383.2%
Avg target
Bull Case
$6.69
+462.2%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$1.94
-38.7% from high
52-Week Low
$0.66
+80.0% from low
Target vs 52W High
$5.75
+196.4% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 69% $257.58 +19.8%
AMGN
Amgen Inc
Hold 42 50% $190.87 -46.0%
GILD
Gilead Sciences Inc
Strong Buy 38 79% $362.68 +158.5%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 -2.0%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.1%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 78% $102.31 -68.9%
INSM
Insmed Inc
Strong Buy 26 92% $143.40 -13.0%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -29.7%